$5,000 TRADING COMPETITION
We’re launching a new challenge to find out which asset class is more profitable for traders.
Team Crypto: $BTC, $ETH, $SOL, $XRP, $HYPE
Team Finance: $NVDA, $MSFT, $TSLA, $PAXG, $XAG
The winning team takes it all.
Join here → https://t.co/uphTXGmM4z
We're one week into the Crypto vs Finance competition, and Team Finance is leading.
$META, $MSFT, $AMZN, and $NVDA hourly markets our trader's favorites.
Top 100 traders on the winning team split the $5K prize pool. Team Finance still has only ~70 traders.
Join here → https://t.co/uphTXGnjU7
$5,000 TRADING COMPETITION
We’re launching a new challenge to find out which asset class is more profitable for traders.
Team Crypto: $BTC, $ETH, $SOL, $XRP, $HYPE
Team Finance: $NVDA, $MSFT, $TSLA, $PAXG, $XAG
The winning team takes it all.
Join here → https://t.co/uphTXGmM4z
BREAKING: Iovance $IOVA is up ~18% today after its cancer treatment got approved in Australia.
But this is just half the entire story.
Here's the full $IOVA growth thesis:
1. In Q1 2026, product revenue was about $71M, up about 45% YoY, with FY2026 revenue guidance of $350M–$370M.
2. Australia approval for Amtagvi adds another market for expansion, and Iovance said it is working to authorize its first Australian treatment center. Australia has an estimated 17,000 melanoma cases annually and over 1,500 deaths annually.
3. Amtagvi demand is expanding across more than 90 U.S. and Canadian authorized treatment centers, with a target of at least 110 ATCs by year-end 2026.
4. TIL therapy can move beyond melanoma into other solid tumors. Iovance has programs in frontline melanoma, NSCLC, endometrial cancer, sarcoma, and next-gen engineered TILs.
5. Next-gen upside FDA clearance for IOV-5001 lets Iovance begin a Phase 1/2 trial in 2H 2026 across colorectal, triple-negative breast, estrogen receptor-low breast, and other solid tumors.
MAG 7 has an intruder:
🟢 $AMZN: +19%
🟢 $NVDA: +19%
🟢 $GOOGL: +18%
🟢 $AAPL: + 17%
🟢 $TSLA: + 7%
🟢 $MSFT: +5%
🔴 $META: -4%
Can I buy this in the metaverse?
If you bought $100 of "No" shares on $HYPE closing green today on Limitless, you'd have $700 now.
The odds dropped from 86% to 3% after Arthur Hayes announced he sold all his $HYPE holdings.
Trade $HYPE markets on Limitless → https://t.co/doZaMfBaFp
BREAKING: Cardano founder Charles Hoskinson says he's "taking a break"
$ADA is currently down -93% since its all-time high.
Is Cardano officially over?
Trump said Nokia $NOK "a great" company and "a leader in 5G"
$NOK is already up 160% in 2026, and NVIDIA announced they doubled its share in Nokia.
Could it be the next $INTC?
People view $BB and $NOK as dead phone producers.
Yet, both stocks are up +180% and +164% in 2026.
Here's why:
$BB:
The market stopped seeing it as a dead phone brand and started pricing it as a high-margin embedded software company.
QNX is already inside 275M+ vehicles, growing double digits, carrying an almost $950M royalty backlog, and expanding into robotics, medical, industrial, defense, and edge AI.
$BB = failed phone company rerated into safety-critical software / automotive OS play.
$NOK:
AI data centers need more than GPUs. They need optical networks, routing, fiber, and high-capacity connectivity between AI clusters.
Nokia’s AI & Cloud revenue is accelerating, optical/IP networks are growing fast, Infinera strengthens the optical story, and NVIDIA’s investment gives the market a clean AI-RAN/6G catalyst.
$NOK = boring 5G vendor rerated into AI networking / optical infrastructure play.
Which "dead stock" will market decide to revive next?
$LUMN, $CIEN, $GLW, $COHR?
SAP $SAP
Enterprise software company best known for ERP, cloud business applications, finance, supply chain, and business AI tools.
Market cap: $222.0B
P/E: 25.7x
EPS: $7.28
TTM revenue: €37.34B
Revenue growth: +6.25% YoY
NVIDIA’s CEO has been dropping companies he's bullish on in nearly every recent public appearance.
Here are the 10 stocks Jensen Huang has been constantly highlighting: